Navigation Links
Use of Rx to OTC Switch as Product Management Tactic Enjoys Comeback
Date:4/10/2008

NEW YORK, April 10 /PRNewswire/ -- There are 14 prescription drugs that exceeded $20 billion in sales in 2006, that may have the potential to reach the over-the-counter market in four years. Prescription to OTC switches were frequent in 2006 and 2007 and a new report by Kalorama Information, The Return of the Rx to OTC Switch: Market Analysis and Product Management Strategies, predicts this trend will continue.

The markets for Rx to OTC are forecast to reach $5 billion in 2008 and increase by close to 40% by 2010. More than half of the revenues in 2008 will be from allergy medications that have already made the switch, such as Claritin, Benadryl, Sudafed, Nasalcrom, Mucinex and most recently Zyrtec. However, the forecast compound annual growth rate from antilipidemic agent switches between 2008 and 2013 far outpaces that of the allergy category (127.5% versus 3%).

"Lagging FDA approvals led to a brief absence of Rx to OTC switches in the pharmaceutical marketplace, but 2006 and 2007 saw a number of switches," notes Melissa Elder, the report's author. "We believe this product management tactic will continue to be aggressively utilized as companies seek ways to extend revenue lifecycles."

Factors affecting this recent upswing in Rx to OTC switches include patent expirations, generic competition, suitability for OTC shelves, drug safety and efficacy, petitions to the FDA and manufacturer trends. Some future potential switches include leading gastrointestinal drugs Prevacid, Protonix and AcipHex; antilipidemic agents Mevacor, Pravachol, Lescol and Zocor; the allergy treatment Allegra; the migraine therapy Imitrex, and a number of oral contraceptives.

Kalorama Information's report Return of the Rx to OTC Switch: Market Analysis and Product Management Strategies contains a complete overview of the U.S. market for prescription drugs likely to switch in 14 different drug categories. Forecasts are provided for each segment for the years 2008 to 2013. The report includes current issues and trends affecting the industry and identifies trends that may arise in the future. The information and forecasts were gathered through secondary research and interviews conducted with industry executives. The report can be purchased directly from Kalorama Information by visiting http://www.kaloramainformation.com/Return-Rx-OTC-1692599/.

About Kalorama Information

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. Kalorama routinely assists media with healthcare topics, and can provide experts to speak about markets in the life sciences industry. For more information, contact Andrea Hiller at 212-807-2673 or press@kaloramainformation.com, or visit http://www.kaloramaInformation.com.


'/>"/>
SOURCE Kalorama Information
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nanoswitches toggled by light
2. New FTMS System From Varian, Inc. Offers Switchable LC and GC Sources and True Triple Quadrupole Capabilities
3. Ultrafast optical shutter is switched entirely by laser light
4. BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology
5. PerOs obtains USDA Establishment and Product Licenses for its oral vaccine formulations
6. U.S. Army Awards General Dynamics Contract for Biological Detection System Production and Support
7. Bluestar Silicones Introduces Three New Soft and Durable Liquid Silicone Rubber Products
8. Campbell Alliance Managed Markets Practice to Take a Leadership Role at the CBI Forum on Effective Product Pricing and Modeling Strategies
9. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
10. Excipients Help Pharma Extend Product Life, Profits
11. ActivBiotics Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... June 28, 2017 Michael Zasloff , ... University School of Medicine, and Founder, Chairman and CEO ... study that has helped clarify the function of alpha-Synuclein ... other neurodegenerative diseases. Denise Barbut , MD, FRCP, ... was senior co-author of the study. Published ...
(Date:6/28/2017)... ... June 28, 2017 , ... ... three research projects accepted for presentation at the 33rd Annual Meeting of the ... – including some of the world’s top thought leaders in reproductive medicine – ...
(Date:6/28/2017)... and London, June 28, 2017 (PRWEB) , ... ... ... The latest release of Siemens’ STAR-CCM+® software for multiphysics computational fluid ... enable automated product design exploration and optimization. STAR-CCM+ version 12.04 introduces Design ...
(Date:6/28/2017)... NC (PRWEB) , ... June 28, 2017 , ... Studies ... might lead to an effective treatment for Parkinson’s disease. But what has not been ... should take place to gain the best results. , A new study coming out ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 8.8% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):